Narayana Hrudayalaya Limited share price

Key numbers

Market cap

₹ 37,805 Cr

Current price

₹ 1,861.40

52-week high / low

₹ 2,093 / 1,589

Stock P/E

46.1

Book value

₹ 223.4

Dividend yield

0.24%

ROCE

14.7%

ROE

19.7%

Debt to equity

1.29

Sales growth (3 yrs)

20.5%

Profit growth (3 yrs)

9.9%

1-year return

8.1%

About Narayana Hrudayalaya Limited

Narayana Hrudayalaya Limited provides medical and healthcare services in India, the United Kingdom, and the Cayman Islands. It operates through the Medical and Healthcare Related Services; and Others segments. The company offers oncology, anesthesiology, audiology, blood bank, breast oncology, oncoplastic surgery, cardiac surgery, cardiology, clinical genetics, clinical immunology, clinical nutrition and dietetics, clinical psychology, congenital adult heart disease, cosmetology, cranio-maxillofacial surgery, critical care medicine, dental, dermatology, diabetology, ENT, emergency medicine, endocrinology, family medicine, general and GI surgery, general medicine and surgery, geriatric medicine, gynecology, hematology, headache and facial pain management, transplant, infectious diseases, neurology, radiology, hepatobiliary surgery, gastroenterology, minimal access GI and bariatric surgery, neonatology, nephrology, neuro-otology, neuro-rehabilitation, neurosurgery and spine surgery, and nuclear medicine services. It also provides ophthalmology, orthopedics and joint replacement, pain management and palliative care, pathology, perinatology and fetal intervention, physical medicine…

Quarterly results

Consolidated figures in ₹ crores

Concall summary (2026-08-10)

AI summary of the earnings call transcript · tone: Positive · source document

Guidance & outlook

• Group Company Secretary, Legal & Compliance Officer “Narayana Hrudayalaya Limited Quarter 1 FY27 Earnings Call” August 03, 2026 DR.
• In the consolidated financials, there's a jump in professional fees paid to doctors from INR 244 crores in Q4 FY26 to INR 327 crores in Q1 FY27 without increase in volumes.

Growth & demand

• I think the EBITDA growth of 40% despite not adding any beds in the last 7 to 8 years is quite remarkable.
• And moving on to the Cayman hospitals, I mean, the growth this quarter in USD terms is a bit soft in like 6%.

Margins & costs

• Just on margins front, you made a point of the 24% EBITDA margin.
• If you look at the India business per se, including combining the losses from the clinic business, even if you set that off, the net margin has expanded by 400 bps year-on- year.

Capex & expansion

• And that is what is giving us the expansion that we are seeing in margins in addition to footfalls that Venkatesh talked about.
• Narayana Hrudayalaya Limited August 03, 2026 Yes, the business we acquired was 95% NHS.

Balance sheet & cash

• Having said that, we have to make a choice on the leverage benefit.
• It is not possible to give a projection on that, but what we can definitely see is that we will see expansion in the core operating margin of the business, given the leverage benefit that we will enjoy.

Peers in Medical Care Facilities

• Apollo Hospitals Enterprise Limited
• Max Healthcare Institute Limited
• Manipal Health Enterprises Limited
• Aster DM Quality Care Limited
• Fortis Healthcare Limited
• Global Health Limited
• Krishna Institute of Medical Sciences Limited
• Rainbow Children's Medicare Limited
• Park Medi World Limited
• Yatharth Hospital & Trauma Care Services Limited